With the right treatment, inflammation can be managed more effectively
Could it have unforeseen effects on organ function

Medicare Guidelines for Syncope Medical necessity for ED visits: Syncope alone supports Level 4 or Level 5 ED visit (CPT 99284 or 99285) based on: Moderate to high severity problem Moderate to high risk of morbidity without treatment Potential for sudden death if cardiac cause Expected workup for R55: EKG (required, considered standard of care) Orthostatic vital signs (expected in most cases) Cardiac monitoring (if any cardiac risk factors) Basic labs (CBC, BMP, glucose at minimum) Observation status criteria: Medicare supports observation for syncope when: Patient has cardiac risk factors Evaluation requires extended monitoring Diagnosis remains unclear after initial workup Patient needs to be observed for recurrence Two-Midnight Rule: Syncope admissions are generally not expected to meet two-midnight criteria unless: Significant comorbidities present Extensive workup required Hemodynamically unstable High risk features requiring prolonged monitoring Commercial Payer Considerations Pre-authorization for advanced testing: Many commercial payers require pre-authorization for: Tilt table testing Electrophysiology studies Implantable loop recorders Cardiac catheterization Ensure medical necessity is clearly documented with: Recurrent unexplained syncope High-risk features Failed initial workup Suspected serious cardiac cause Documentation requirements for telemetry: Telemetry monitoring must be justified with documented: Cardiac risk factors Abnormal EKG findings History of arrhythmia Concerning symptoms (chest pain, palpitations) Simply coding R55 without supporting documentation for high-risk features may result in telemetry denial

The pace of free radical generation, however, can often surpass the cellular production of glutathione (GSH), leading to a cascade of oxidative stress, chronic inflammation and tissue damage
Do not freeze the reconstituted liquid, as the freeze-thaw cycle can damage the peptide structure